ReP USP - Resultado da busca

Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 06 nov. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial (2021)
Butt, Jawad H; Nicolau, Jose Carlos ; Verma, Subodh; Docherty, Kieran F; Petrie, Mark C; Inzucchi, Silvio E; Schou, Morten; Kosiborod, Mikhail N; Langkilde, Anna Maria; Martinez, Felipe A
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, GLICOSÍDEOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, v. 23, n. 4, p. 601-613, 2021Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2124. Acesso em: 06 nov. 2024.
APA
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., et al. (2021). Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 23( 4), 601-613. doi:10.1002/ejhf.2124
NLM
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1002/ejhf.2124
Vancouver
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1002/ejhf.2124
Artigo de periodico
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes (2020)
Petrie, Mark C; Verma, Subodh; Docherty, Kieran F; Inzucchi, Silvio E; Anand, Inder; Belohlavek, Jan; Boehm, Michael; Chiang, Chern-En; Chopra, Vijay K.; Nicolau, José Carlos
Source: Jama-journal of the american medical association. Unidade: FM
Subjects: DIABETES MELLITUS, MÉTODO DUPLO-CEGO, HEMOGLOBINAS, INSUFICIÊNCIA CARDÍACA, FÁRMACOS (METABOLISMO E NUTRIÇÃO), PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRIE, Mark C et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, v. 323, n. 14, p. 1353-1368, 2020Tradução . . Disponível em: https://doi.org/10.1001/jama.2020.1906. Acesso em: 06 nov. 2024.
APA
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlavek, J., et al. (2020). Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, 323( 14), 1353-1368. doi:10.1001/jama.2020.1906
NLM
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1001/jama.2020.1906
Vancouver
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1001/jama.2020.1906
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 06 nov. 2024.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 06 nov. 2024.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies